SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

Clarification to IRB Reporting Criteria for Gene Transfer Protocols

May 30, 2018 - SCI Communications

There is a new clarification to the IRB reporting criteria for Gene Transfer protocols. The guidance clarifies that SAE’s that meet the criteria for an Unanticipated Problem (unexpected, related to the research and harmful) need to be promptly reported to the IRB. Please refer to the IRB Prompt Reporting Guidance for further information. All adverse events (expected events and other unrelated events) still need to be reported to the IRB at the time of continuing review.

Please note that this clarification is ONLY for IRB reporting. Other reporting as required by the Biosafety Panel or other departments should continue as directed.

Feel free to contact Shana Stolarczyk, Senior IRB Manager, Panel 1, if you have any questions.

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube